Molecular Characterization of Prostate Cancer with Associated Gleason Score Using Mass Spectrometry Imaging.
Journal
Molecular cancer research : MCR
ISSN: 1557-3125
Titre abrégé: Mol Cancer Res
Pays: United States
ID NLM: 101150042
Informations de publication
Date de publication:
05 2019
05 2019
Historique:
received:
28
09
2018
revised:
19
12
2018
accepted:
06
02
2019
pubmed:
13
2
2019
medline:
29
4
2020
entrez:
13
2
2019
Statut:
ppublish
Résumé
Diagnosis of prostate cancer is based on histologic evaluation of tumor architecture using a system known as the "Gleason score." This diagnostic paradigm, while the standard of care, is time-consuming, shows intraobserver variability, and provides no information about the altered metabolic pathways, which result in altered tissue architecture. Characterization of the molecular composition of prostate cancer and how it changes with respect to the Gleason score (GS) could enable a more objective and faster diagnosis. It may also aid in our understanding of disease onset and progression. In this work, we present mass spectrometry imaging for identification and mapping of lipids and metabolites in prostate tissue from patients with known prostate cancer with GS from 6 to 9. A gradient of changes in the intensity of various lipids was observed, which correlated with increasing GS. Interestingly, these changes were identified in both regions of high tumor cell density, and in regions of tissue that appeared histologically benign, possibly suggestive of precancerous metabolomic changes. A total of 31 lipids, including several phosphatidylcholines, phosphatidic acids, phosphatidylserines, phosphatidylinositols, and cardiolipins were detected with higher intensity in GS (4+3) compared with GS (3+4), suggesting they may be markers of prostate cancer aggression. Results obtained through mass spectrometry imaging studies were subsequently correlated with a fast, ambient mass spectrometry method for potential use as a clinical tool to support image-guided prostate biopsy. IMPLICATIONS: In this study, we suggest that metabolomic differences between prostate cancers with different Gleason scores can be detected by mass spectrometry imaging.
Identifiants
pubmed: 30745465
pii: 1541-7786.MCR-18-1057
doi: 10.1158/1541-7786.MCR-18-1057
pmc: PMC6497547
mid: NIHMS1521525
doi:
Substances chimiques
Biomarkers, Tumor
0
Types de publication
Journal Article
Research Support, N.I.H., Extramural
Langues
eng
Sous-ensembles de citation
IM
Pagination
1155-1165Subventions
Organisme : NCI NIH HHS
ID : R01 CA201469
Pays : United States
Organisme : NHLBI NIH HHS
ID : T32 HL007627
Pays : United States
Organisme : NIBIB NIH HHS
ID : P41 EB015898
Pays : United States
Organisme : NCI NIH HHS
ID : R25 CA089017
Pays : United States
Organisme : NICHD NIH HHS
ID : U01 HD087211
Pays : United States
Informations de copyright
©2019 American Association for Cancer Research.
Références
Oncotarget. 2017 May 17;8(49):84902-84916
pubmed: 29156692
Oncotarget. 2017 Jul 11;8(28):45190-45199
pubmed: 28423352
Biomark Insights. 2011 Mar 14;6:39-47
pubmed: 21499438
Nucleic Acids Res. 2018 Jan 4;46(D1):D608-D617
pubmed: 29140435
Prostate. 2009 Sep 15;69(13):1470-9
pubmed: 19462462
Cancer. 1953 Sep;6(5):963-8
pubmed: 13094644
Radiology. 2015 Jan;274(1):170-80
pubmed: 25222067
Nat Rev Urol. 2011 May 17;8(6):301-11
pubmed: 21587223
Mol Cell Biochem. 2015 Dec;410(1-2):175-85
pubmed: 26314254
Mol Cell Proteomics. 2016 Jan;15(1):154-63
pubmed: 26545398
Cancer Epidemiol Biomarkers Prev. 2016 Jun;25(6):887-906
pubmed: 27197278
Anal Chem. 2011 Nov 15;83(22):8366-71
pubmed: 21975048
Int J Oncol. 2016 Oct;49(4):1541-1552
pubmed: 27634112
CA Cancer J Clin. 2016 Jul;66(4):271-89
pubmed: 27253694
Analyst. 2013 Mar 7;138(5):1289-315
pubmed: 23314100
PLoS One. 2015 Mar 13;10(3):e0119314
pubmed: 25767870
Int J Mass Spectrom. 2015 Feb 1;377:690-698
pubmed: 25844057
Prostate. 2015 Dec;75(16):1821-30
pubmed: 26332786
Nucleic Acids Res. 2007 Jul;35(Web Server issue):W606-12
pubmed: 17584797
Prostate. 2010 May 15;70(7):710-7
pubmed: 20017167
Am J Surg Pathol. 1988 Dec;12(12):897-906
pubmed: 3202246
Proc Natl Acad Sci U S A. 2014 Oct 21;111(42):15184-9
pubmed: 25246570
Proc Natl Acad Sci U S A. 2017 Mar 28;114(13):3334-3339
pubmed: 28292895
Br J Cancer. 2015 Dec 22;113(12):1712-9
pubmed: 26633561
Mol Cancer Res. 2017 Apr;15(4):439-447
pubmed: 28074002
J Mass Spectrom. 2013 Nov;48(11):1178-87
pubmed: 24259206
Sci Rep. 2016 Feb 11;6:20984
pubmed: 26865432
Cell Death Dis. 2016 May 19;7:e2226
pubmed: 27195673
Oncogene. 2017 Oct 26;36(43):6030-6040
pubmed: 28671672
JAMA. 2017 Jun 27;317(24):2532-2542
pubmed: 28655021
Nat Rev Cancer. 2018 Jan;18(1):19-32
pubmed: 29217838
Nucleic Acids Res. 2018 Jul 2;46(W1):W486-W494
pubmed: 29762782
N Engl J Med. 2018 May 10;378(19):1767-1777
pubmed: 29552975
Hum Pathol. 2017 May;63:202-211
pubmed: 28315427
J Urol. 1974 Jan;111(1):58-64
pubmed: 4813554
Int J Cancer. 2016 Jun 15;138(12):2884-93
pubmed: 26860439
JAMA. 2015 Jan 27;313(4):390-7
pubmed: 25626035
Eur Urol. 2016 Mar;69(3):428-35
pubmed: 26166626
J Urol. 2013 Jun;189(6):2039-46
pubmed: 23485507
Proc Natl Acad Sci U S A. 2014 Jul 29;111(30):11121-6
pubmed: 24982150
Biochim Biophys Acta Proteins Proteom. 2017 Jul;1865(7):755-767
pubmed: 28017863
Chem Rev. 2011 Oct 12;111(10):6491-512
pubmed: 21942646
Anal Chem. 2018 Apr 17;90(8):4987-4991
pubmed: 29608279